REDWOOD CITY, Calif., May 22, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for the efficient and scalable manufacturing of complex therapeutics, ...
Guidance holds steady: Management kept its 2026 revenue target at $72–$76 million, expecting stronger results in the second half. Scaling ambitions: A 0.5 kilogram ECO Synthesis siRNA production scale ...
VANCOUVER, British Columbia, April 12, 2011 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, announced ...
Q1 2026 Management view Dr. Alison Moore said the company “accomplished a lot” since the prior call and plans to present “important new data on our ECO Synthesis technology” at the TIDES Conference, ...
Hongene Biotech shows advanced oligonucleotide CDMO capabilities via support of SiranBio’s dual-target siRNA programme: Singapore Saturday, May 9, 2026, 16:00 Hrs [IST] Hongene ...
Revenue guidance for 2026 is reiterated at $72 million to $76 million, with expectations for performance to be more heavily ...
VANCOUVER, British Columbia, Nov. 22, 2010 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (TSX:TKM) (Nasdaq:TKMR), a leading developer of RNA interference (RNAi) therapeutics, announced today ...
REDWOOD CITY, Calif., Dec. 13, 2023 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced it has achieved gram-scale synthesis with its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results